CELL & GENE THERAPY INSIGHTS

Spotlight

Immuno-oncology: manufacturing and commercial business models for the new decade

Jul 2020
Guest Editor:
Usman Azam, President & CEO at Tmunity Therapeutics Inc
Usman Azam
President & CEO at Tmunity Therapeutics Inc

Foreword


Expert Insight


Innovator Insight

Simplifying GMP CART and CAR NK cell therapy manufacturing processes

Sarah Dluczek,
Kate Fynes,
Stephan Fricke,
Ulrike Koehl,
Martha Luevano,
Xiuyan Wang
16 July 2020
Innovator Insight

Interview


Expert Roundtable Video

Expert Roundtable: evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

Derek Adams,
Greg Russotti,
John Lunger,
Evonne Fearnot,
Emilie Gauthy
17 July 2020
Expert Roundtable Video

Expert Roundtable

Evolving autologous and allogeneic cell therapy manufacturing models in the commercial setting

Derek Adams,
Greg Russotti,
John Lunger,
Evonne Fearnot,
Emilie Gauthy
16 July 2020
Expert Roundtable

Vectors FOCUS

Report

Commercial Insights

Cell & Gene Therapy Commercial Insight - May 2020

Mark Curtis,
Richard Philipson
24 June 2020
Commercial Insights

Report

Other articles

Preliminary Communication

A proposed protocol of derived mesenchymal stem cells for the treatment of COVID-19 patients

Vasiliki Kalodimou,
Alma Reyes-Calavera
10 July 2020
Preliminary Communication

Webinars

Simplifying GMP CAR-T and CAR NK cell therapy manufacturing processes

Simplifying GMP CAR-T and CAR NK cell therapy manufacturing processes

Martha Luevano
Martha Luevano, Global Product Manager at Miltenyi Biotec
Xiuyan Wang
Xiuyan Wang, Assistant Director, Michael G. Harris Cell Therapy & Cell Engineering Facility at Memorial Sloan-Kettering Cancer Center
Stephan Fricke
Stephan Fricke, Head of GMP Process Development at Fraunhofer Institute for Cell Therapy & Immunology IZI
Sarah Dluczek
Sarah Dluczek, Technical Leader, GMP Unit at Fraunhofer Institute for Cell Therapy & Immunology IZI
Kate Fynes
Kate Fynes, Process Development Investigator, Cell & Gene Therapy CMC at GlaxoSmithKline
Ulrike Koehl
Ulrike Koehl, Director & Head, Institute of Cell Therapeutics & GMP Development Unit at Hannover Medical School
9 June 2020
Webinar
Challenges of cell collections for cell therapy manufacturing: what do we want in the bag?

Challenges of cell collections for cell therapy manufacturing: what do we want in the bag?

Elizabeth Valdez
Elizabeth Valdez, RN & MSN Global Trainer at Terumo BCT
Jim Beltzer
Jim Beltzer, Global Strategy Lead, Cell Therapy
Sandeep Soni
Sandeep Soni, Associate Professor, Pediatric Stem Cell Transplant, Gene Therapy & Regenerative Medicine at Stanford University School of Medicine
Melinda Caltabiano
Melinda Caltabiano, Director, Apheresis Operations at Dendreon Pharmaceuticals
Krishnendu Roy
Krishnendu Roy, Professor, Director, Marcus Center for Therapeutic Cell Characterization & Manufacturing (MC3M) at Georgia Institute of Technology
24 June 2020
Webinar
Manufacturing of endogenous, non-engineered, antigen specific T cells against tumor targets

Manufacturing of endogenous, non-engineered, antigen specific T cells against tumor targets

Ali Mohamed
Ali Mohamed, Vice President, CMC at Immatics
Megan Ciarlo
Megan Ciarlo, Technology & Applications Specialist at Miltenyi Biotec
14 July 2020
Webinar
Identifying the critical factors for commercial-scale viral vector process development and manufacturing

Identifying the critical factors for commercial-scale viral vector process development and manufacturing

Behnam Baghbaderani
Behnam Baghbaderani, Global Head, Process Development, Emerging Technologies at Lonza Pharma & Biotech
Xin Swanson
Xin Swanson, Head, Business Development, Viral-based Therapeutics at Lonza Pharma & Biotech
Suparna Sanyal
Suparna Sanyal, Head of Viral Vectors Commercial Development, Lonza Pharma & Biotec
26 August 2020
Webinar